Search

Displaying results 5871 - 5880 of 10000 in total
  1. Drug

    AVI-7537

    go.drugbank.com/drugs/DB15433
    Investigational

    [L46207] AVI-7537 is under investigation in clinical trial NCT01593072 (A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers). … AVI-7537 is an antisense molecule that binds to the Ebola virus mRNA to prevent the viral replication.

  2. Drug

    Fucoxanthin

    go.drugbank.com/drugs/DB15462
    Investigational

    In vivo studies have demonstrated that oral administration of fucoxanthin inhibited carcinogenesis in an animal model of duodenal, skin, colon and liver cancer. … Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion).

  3. Drug

    Olinciguat

    go.drugbank.com/drugs/DB15238
    Investigational

    , Olinciguat (IW-1701), in Healthy Volunteers). … Olinciguat is under investigation in clinical trial NCT03892499 (A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator

  4. Drug

    Metribolone

    go.drugbank.com/drugs/DB02998
    Experimental

    It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.

  5. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause

  6. Drug

    SR 121463

    go.drugbank.com/drugs/DB05455
    Investigational

    It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).

  7. Drug

    Gemifloxacin

    go.drugbank.com/drugs/DB01155
    ApprovedInvestigational

    Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. … It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.

  8. Drug

    Londamocitinib

    go.drugbank.com/drugs/DB19190
    Investigational

    Londamocitinib is under investigation in clinical trial NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-severe Asthma Uncontrolled on Medium-high

    Synonyms: (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide, 1-piperazineacetamide, n-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.-(methoxymethyl)-4-methyl-, (.alpha.r)-
  9. Drug

    Carbenoxolone

    go.drugbank.com/drugs/DB02329
    Experimental

    An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. … Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]

  10. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    Reglagene announced FDA orphan drug designation for glioblastoma in 2024. RGN6024 remains investigational and is not an approved drug. … cells, and suppresses tumor growth in glioblastoma xenograft models.